Finally, poor survival rates were observed in patients with low expression levels of STXBP6. Thus, methylation-driven, differentially expressed STXBP6 may be used as a novel biomarker to predict clinical outcomes of lung adenocarcinoma patients. This evidence concerns the gene STXBP6 and lung adenocarcinoma.